Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.

Hepato-gastroenterology - 1 Jan 2000

Katano Yoshiaki, Kumada Takashi, Nakano Isao, Toyoda Hidenori, Ishigami Masatoshi, Hayashi Kazuhiko, Honda Takashi, Goto Hidemi

Abstract excerpt

BACKGROUND/AIMS: Although the efficacy and safety of pegylated-interferon (PEG-IFN) alpha-2a and PEG-IFN alpha-2b have been comparatively studied, there are few study results available in which the two PEG-IFN products were strictly compared. To compare the effects of two PEG-IFN products on blood cell profile. METHODOLOGY: The time-course change in blood cell counts was compared between chronic hepatitis C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Count

Share to Platelet Count

Share to Polyethylene Glycols

Share to Ribavirin

Share to Safety

Share to Statistics, Nonparametric

Source

Identifiers

PMID: 19579626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.PMID 19579626Read ↗

Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.Semantic proximity Read ↗

Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.Semantic proximity Read ↗

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.Semantic proximity Read ↗

Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2.Semantic proximity Read ↗

Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.Semantic proximity Read ↗

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.Semantic proximity Read ↗

Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.Semantic proximity Read ↗

Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.Semantic proximity Read ↗

Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.Semantic proximity Read ↗

Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.Semantic proximity Read ↗

Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.